Structured abstract
Objective To determine whether naturally occurring autoantibodies against the prion protein are present in individuals with genetic prion disease mutations and controls, and if so, whether they are protective against prion disease.
Methods In this case-control study, we collected 124 blood samples from individuals with a variety of pathogenic PRNP mutations and 78 control individuals with a positive family history of genetic prion disease but lacking disease-associated PRNP mutations. Antibody reactivity was measured using an indirect ELISA for the detection of human IgG1-4 antibodies against wild-type human prion protein. Multivariate linear regression models were constructed to analyze differences in autoantibody reactivity between a) PRNP mutation carriers versus controls and b) asymptomatic versus symptomatic PRNP mutation carriers. Robustness of results was examined in matched cohorts.
Results We found that antibody reactivity was present in a subset of both PRNP mutation carriers and controls. Autoantibody levels were not influenced by PRNP mutation status nor clinical manifestation of prion disease. Post hoc analyses showed anti-PrPC autoantibody titers to be independent of personal history of autoimmune disease and other immunological disorders, as well as PRNP codon 129 polymorphism.
Conclusions Pathogenic PRNP variants do not notably stimulate antibody-mediated anti-PrPC immunity. Anti-PrPC IgG autoantibodies are not associated with the onset of prion disease. The presence of anti-PrPC autoantibodies in the general population without any disease-specific association suggests that relatively high titers of naturally occurring antibodies are well tolerated. Clinicaltrials.gov identifier NCT02837705.
Introduction
Prion diseases are diseases of the central nervous system which not only occur as sporadic and transmissible forms, but can also be transmitted through the germ line as autosomal dominant traits 1. Genetic prion diseases (gPrDs) account for ∼ 10-15 % of all prion diseases and are characterized by pathogenic, non-synonymous mutations of the human prion protein gene PRNP 2. The most prevalent human prion disease, sporadic Creutzfeldt-Jakob disease (sCJD), is characterized by a rapidly progressive dementia and a short survival time (usually < 1 year) from clinical onset 3. In contrast, PRNP mutation carriers often present with atypical phenotypes, e.g. long survival rates can be observed in Gerstmann-Sträussler-Scheinker disease (GSS) 4.
The cellular prion protein PrPC consists of an unstructured, flexible tail (FT) on its N-terminal end and a C-terminal globular domain (GD) 5. We have shown in 2001 that humoral immunity against PrPC can protect against prion neuroinvasion 6. Antibodies against the FT of PrPC, or removal of amino acid residues from the FT, abrogate the neurotoxic effects of anti-PrPC-GD antibodies and reduce the toxicity of bona fide prions 7, 8. Naturally occurring PrP antibodies may exist in the general population: for instance, reactivity against a 21-residue PrP peptide was observed in commercial pooled immunoglobulin 9, and a unique blood group has been observed in individuals homozygous for the E219K polymorphism 10.
Clinical trials have yet to deliver an effective anti-prion agent so far 11-14. An ongoing clinical study involves the administration of PRN100, a humanized antibody against PrPC-GD, to individuals suffering from CJD 15. While there is much hope that this trial will be successful, the murine counter-part of PRN100, ICSM18, exhibits an on-target, dose-dependent toxicity, and whether a therapeutic window exists has not yet been established 16-18.
The frequency of PRNP missense variants exceeds the reported genetic prion disease prevalence, suggesting a spectrum of disease penetrance in gPrDs rather than complete penetrance of non-synonymous PRNP mutations 19. The mechanisms by which these mutations induce disease are still largely unclear. The majority of structural studies on human PrPC variants linked to genetic prion disease failed to identify consistent effects on global protein stability 20. Age of onset in gPrD is highly variable, and typically middle age or older, which might suggest that a protective mechanism guards some individuals against the prion protein-induced toxicity 2. We hypothesized that subtle conformational alterations of pathogenic PrPC variants could stochastically generate immunogenic neo-epitopes, which in turn might elicit a protective humoral anti-PrPC immune response. We therefore conducted an extensive search for such autoantibodies in individuals carrying pathogenic PRNP mutations, and in unaffected relatives as controls.
Material and Methods
Ethics statement
The Cantonal Ethics Committee of the Canton of Zurich approved this study (permit no. “KEK-ZH Nr.2015-0514”). This trial was registered at clinicaltrials.gov (no. NCT02837705). The protocol for this study was approved by the institutional review board at each participating institution with the University of Zurich being the lead regulatory site. Written informed patient consent was received by all individuals participating in this study.
Human subjects and study design
We defined PRNP mutation carriers as individuals with a non-synonymous mutation in the open reading frame of the PRNP gene that was previously reported to be pathogenic 2. Between September 2015 and October 2018, we contacted both international patient organizations as well as national prion disease reference centers for further re-use of existing blood samples. Individuals at any age with a confirmed PRNP mutation were considered eligible for this study. Individuals with a confirmed PRNP mutation in a blood relative who did not undergo PRNP sequencing prior to enrollment in this study were also considered eligible if they gave consent for PRNP sequencing. Blood samples without information on age or gender were excluded from further analysis. PRNP wild-type individuals with neurological or psychiatric symptoms indicative of genetic prion disease were excluded from the study 21. Clinical manifestation of gPrD was defined as presence of both a pathogenic PRNP mutation and PrD-typical symptoms 21. The latter were assessed by clinical exam and neuropsychological assessment, in some cases complemented by ancillary tests such as presence of 14-3-3 proteins in cerebrospinal fluid, real-time quaking-induced conversion (RT-QuIC) assays, electroencephalography and magnetic resonance imaging 22. Personal history of autoimmune disease and other immunological disorders could be obtained in n = 141 of participants. A detailed description of the patient cohort is given in table 1. For sensitivity analysis, cases and controls were matched on age (± 5 years), gender and blood sample type (i.e. serum or plasma).
PRNP genotyping
PRNP genotyping was performed using a modified version of the DNeasy Blood & Tissue Kit (Qiagen). 20 μL of PK (600 mAU/ml) and 200 μL of 5 M guanidine hydrochloride (GdnHCl) with 1% Triton-X100 at pH = 5.0 were added to 200 μL of anticoagulated blood, vortexed thoroughly and incubated for 24 h at room temperature. 200 μL EtOH (96-100%) were added to the reaction and the rest of the DNA purification was performed according to the manufacturer’s guidelines. The primer pair PRNP_up and PRNP_low (table e-1 available from Dryad https://doi.org/10.5061/dryad.08kprr4xk) was used in combination with Q5 high-fidelity DNA polymerase (New England Biolabs) to amplify the open reading frame from exon 2 of PRNP. Sanger sequencing was performed at the Department of Molecular Pathology (Institute of Surgical Pathology, University Hospital Zurich) using four different sequencing primers (PRNP_up, PRNP_up2, PRNP_low, PRNP_low2, table e-1 available from Dryad https://doi.org/10.5061/dryad.08kprr4xk). Sequencing traces were aligned to reference DNA from the Reference Sequence (RefSeq) Database (O’Leary et al. 2016) using CLC Main Workbench (Qiagen) and packages sangerseqr23 and DECIPHER24 for Bioconductor25 in R.
Statistical analyses
We performed a priori testing of anti-PrPC autoantibody reactivity for the following hypotheses: a) differences in anti-PrPC autoantibody reactivity between PRNP mutation carriers and PRNP wild-type individuals and b) differences in anti-PrPC autoantibody reactivity between PRNP mutation carriers showing clinical signs of prion diseases and those without. All other analyses were performed post hoc. We used already established predictors of autoimmune disease such as age 26 and gender 27 as well as storage conditions known to affect antibody responses such as presence of coagulation factors 28 as covariates in our multivariate regression model. Using the purposeful selection of covariates method as described previously 29, effects of covariates on autoantibody titers were tested by bivariate linear regression analyses using the Wald test and included for multivariate testing at a p-value cut-off point of 0.25. In the multivariate model covariates were removed if they were non-significant at the 0.1 alpha level or not a confounder, as determined by a change in the remaining parameter estimate greater than 20 % as compared to the full model. PRNP mutation status, clinical signs of prion disease, PRNP codon 129 polymorphism were added after establishment of significant confounders. In matched cohorts, multivariate models were adjusted for matching factors.
All values are given as average ± standard deviation unless mentioned otherwise. For analysis, autoantibody titers were log10-transformed, and reported β coefficients and confidence intervals represent back-transformed values. Normality was tested using the D’Agostino-Pearson normality test. For values following a Gaussian distribution, differences between two groups were compared using two-tailed student’s T test. For not normally distributed values, Mann Whitney U Test was used for comparison of two groups. For comparison of categorical variables, Fisher’s exact test and chi-squared test were used for comparison of two and more than two groups, respectively. Pearson correlation coefficient was computed for data sampled from Gaussian distributions and Spearman’s rho for those sampled from non-Gaussian distributions. Matching of cases and controls was done using the find.matches function from the Hmisc package in R. We used lm for R for linear regression analysis. Python and R were used for statistical analysis, data visualization was performed using Prism 7 (GraphPad).
Data availability statement
The study participants, if they have not undergone predictive testing themselves, participated under the condition of not knowing their PRNP genotype. Due to the relatively small sample size and risk of de-identification, all raw study data involving human participants was made available to the editors and reviewers but will not be made available publicly. Supplementary data, as well as DNA sequences of gene blocks used for construction of humanized antibodies and human PrPC-AviTag™ are available at Dryad https://doi.org/10.5061/dryad.08kprr4xk.
Results
Description of the cohort
We received blood samples and clinical information from a total of n = 241 individuals and selected n = 202 unmatched cases and controls for this analysis (figure 1). To test the robustness of our results, we matched n = 64 cases on n = 64 controls based on age (± 5 years), gender and blood storage conditions (i.e. serum / plasma, table e-2 available from Dryad https://doi.org/10.5061/dryad.08kprr4xk). Anti-PrPC autoantibody reactivity was measured by a sandwich enzyme-linked immunosorbent assay (ELISA), a description of the assay is provided in extended text and figures e-1 and e-2 available from Dryad https://doi.org/10.5061/dryad.08kprr4xk. Briefly, blood samples were diluted over a range of > 2 logs and bound autoantibodies were detected with anti-human IgG antibodies. Antibody titers are expressed as negative common logarithm of the half-maximal effective concentration (figure e-1E available from Dryad https://doi.org/10.5061/dryad.08kprr4xk). Anti-PrPC antibody reactivity was independent of serum IgG levels (Spearman’s ρ = 0.07, p = 0.69, figure 2A). The age of probands did not influence the IgG levels (Pearson r = 0.33, p = 0.16). To confirm our ability to detect human antibodies against specific targets, we tested a subset of individuals for the presence of IgG against the Epstein-Barr nuclear antigen (EBNA). 4/5 PRNPWT and 16/16 PRNPMut individuals tested positive (corresponding to 95 % positive individuals), in line with anti-EBNA IgG seroprevalence in the general population (figure 2B) 30.
Double line indicates cohorts selected for comparison of anti-PrPC autoantibody titers from individuals carrying wild-type or mutated PRNP alleles (right of double line) and cohort selected for comparing anti-PrPC autoantibody titers of symptomatic versus asymptomatic mutation carriers (left of double line). Blue boxes indicate matched cohorts.
(A) Correlation of total IgG with anti-PrPC autoantibody titers. (B) Qualitative assessment of anti-EBNA IgG antibodies in blood shows one PRNPWT individual without detectable anti-EBNA IgG antibodies. Cut-off: ODabs=450nm (optical density at absorbance α=450 nm) = 0.2 according to the manufacturer’s guidelines. (C) In two subsequent blood drawings, mean change of antibody titers per year is stable and similar between PRNP mutation and wild-type carriers, but variance is larger in PRNP mutation carriers.
Prevalence of anti-PrPC autoantibodies in PRNP mutation carriers
The presence of coagulation factors (e.g. plasma instead of serum), and possibly age, but not female gender were associated with anti-PrPC autoantibody reactivity in bivariate and multivariate analyses (table 2) 29. We henceforth adjusted all analyses for age and presence of coagulation factors. Presence or absence of a pathogenic PRNP mutation was not associated with significant changes in anti-PrPC autoantibody reactivity (table 3). Additionally, we matched both n = 62 cases and controls on age (± 5 years), gender and blood sample type 26-28 (table e-2 available from Dryad https://doi.org/10.5061/dryad.08kprr4xk). As with the unmatched cohort, PRNP mutation did not significantly influence anti-PrPC autoantibody titers in multivariate linear regression adjusted for matching factors (table e-2).
Due to lack of confounding effects of gender in multivariate model B, all further analyses were adjusted for blood sample type (serum/plasma) and age.
We then tested whether anti-PrPC autoantibody response was associated with symptoms of prion disease. Presence or absence of clinical signs was reported by n = 122 PRNP mutation carriers (out of a total of n = 124 enrolled): n = 76 (62.3 %) were asymptomatic carriers whereas n = 46 (37.7%) presented with clinically apparent disease. Detailed clinical data was available in n = 14 cases, the most common clinical presentations entailed cerebellar signs (n = 12, 85.7%) and dementia (n = 11, 78.6%). Status of 14-3-3 protein in cerebrospinal fluid, albeit a poor predictor of genetic prion disease 31, was provided by n = 121 of study participants. N = 17 individuals (all PRNP mutation carriers with clinically apparent disease) were tested with n = 8 (47.1%) being tested positive, in line with previous findings 31. Presence of prion-specific symptoms was not associated with alterations in anti-PrPC autoantibodies in an unmatched cohort (table 3). This was confirmed in an analysis of a cohort consisting of n = 24 symptomatic PRNP mutation carriers and n = 24 asymptomatic PRNP mutation carriers matched on PRNP mutation, age and sample type (table e-2).
Post hoc subgroup analyses on the association of anti-PrPC autoantibodies with specific PrPC mutations, PrPC p.129 polymorphism and autoimmune disease and other immunological disorders
We analyzed the effects of PRNP mutations that were present at least five times in the study population, namely D178N and E200K, on anti-PrPC autoantibody titers: individuals with D178N mutations showed a significant trend towards lower autoantibody titers in bivariate analysis (table 3). This finding, however, was not significant after adjusting for age and sample type (table 3). E200K mutation carriers did not show significant changes in autoantibody reactivity (table 3). The (M)ethionine/(V)aline polymorphism at codon 129 of the human PRNP gene was reported to affect the susceptibility to prion diseases 32. Information on p.129 polymorphism was available in n = 182 of study participants: n = 84 (46.2%) were homozygous for methionine (p.129MM), n = 87 (47.8%) p.129MV, n = 11 (6.0%) p.129VV. None of the polymorphisms significantly altered autoantibody response to PrPC in a post hoc analysis (table 4). In D178N carriers, the clinical phenotype was suggested to be dependent on the PRNP cis c.129 polymorphism: methionine was associated with FFI and valine with fCJD 2, although this association may not be universal 33, 34. In our cohort, n = 28 patients could be unambiguously identified as D178N_cis129M and n = 5 patients as D178N_cis129V. No differences in mean antibody reactivity were seen between those two groups (table 4).
Co-occurrence of multiple autoimmune diseases is a commonly observed phenomenon 35. In order to test the influence of pre-existing autoimmune diseases on anti-PrPC autoantibody titers we searched clinical reports of study participants for presence of autoimmune disease and other immunological disorders. We were able to retrieve this information in n = 141 (69.8 %) of cases: n = 8 individuals were diagnosed with autoimmune disease, namely Hashimoto’s thyroiditis (n = 3), Graves’ disease (n = 1), monoclonal gammopathy of unknown significance (n = 1), multiple sclerosis (n = 1), psoriasis (n = 1) and rheumatoid arthritis (n = 1). Multivariate linear regression analysis adjusted for age, gender and type of blood sample did not show a significant association of autoimmune disease with anti-PrPC autoantibody titers (table 4).
Temporal evolution of anti-PrPC autoantibodies
44 individuals (21.8 %) donated blood multiple times, several months apart on which we performed a post hoc, time course analysis. PRNP wild-type individuals were observed over a longer time period compared to PRNP mutations carriers (17 ± 1.78 months vs. 10 ± 6.21 months, p = 1.42 × 10−5). PRNP mutation carriers showed larger variability in autoantibody titers, mean proportional change per year was, however, similar across groups (p = 0.23) and was overall negligible between two blood drawings (113.2 ± 61.44 % per year in PRNP mutation carriers versus 99.95 ± 17.22 % per year in PRNP wild-type individuals, figure 2C). None of the PRNP mutation carriers tested in this time course analysis exhibited clinical signs of prion disease.
Discussion
The diagnosis of a disease-associated PRNP mutation is a fateful and often devastating event for individuals carrying such mutations. The clinical penetrance of PRNP mutations can be very high, and no disease-modifying therapy is available as of today 2. Clinical signs of familial prion disease typically erupt in late adulthood although carriers arguably produce the mutated protein from the first day of their life 5. There are at least two scenarios that may account for this phenomenon: (1) the pathogenic mutations may slightly destabilize PrPC, thereby infinitesimally increasing the probability of pathological aggregation, or (2) the pathogenic conformation of PrPC is attained early on, but the body’s defenses stave off its consequences for many decades.
In the case of scenario #1, extensive structural studies on pathogenic PrPC variants failed to reveal major structural alterations 20. We hypothesized that under scenario #2, the stochastic generation of PrPSc in mutation carriers might engender neoantigens, which in turn might lead to protective humoral responses. Remarkably, however, we found no evidence of induction of humoral antibody-mediated immunity against PrPC by pathogenic PRNP variants. Instead, our study suggests the prevalence of naturally occurring anti-PrPC antibodies in the general population independent of clinical signs of prion disease, PRNP variant or PRNP p.129 polymorphism. Although reactivity to wild-type PrP has been reported in the serum of E219K homozygotes 10, and reactivity to a non-naturally-occurring PrP peptide was reported in commercial IgG 9, the present report is to our knowledge the first observation of the PRNP genotype-independent presence of autoantibodies to full-length, wild-type PrP in humans. Without disease-specific antibodies, one might speculate that PRNP mutations accumulate subclinical levels of prions to a point when clinical symptoms become evident.
In a subset of individuals, anti-PrPC autoantibody reactivity was tested in multiple blood drawings up to 1.5 years apart: the mean change of autoantibody titers was similar across PRNP genotypes in line with previous reports that showed stable autoantibody levels at least over several years 36, 37.
Matching in case-controls studies is a controversial topic 38. In our study, initial analyses were performed on unmatched cohorts adjusted for known confounders of blood autoantibody levels, this approach was described to increase statistical power 39. To strengthen our arguments, we compared anti-PrPC autoantibody levels in cases and matched controls, these results are in line with findings from the unmatched cohorts.
An increasing number of autoantibodies against neurodegenerative targets are being explored as biomarkers and as potential therapeutics. Naturally occurring autoantibodies against hyperphosphorylated tau protein have been isolated from several asymptomatic blood donors 40. Researchers from Neurimmune (Switzerland) recently reported the development of a fully human antibody against amyotrophic lateral sclerosis targeting pathologically misfolded SOD1, α-miSOD1, from a memory B-cell library from healthy elderly individuals 41. Phase III trials involving aducanumab, a bona fide human antibody with potent β-amyloid clearing capabilities, were, however, stopped prematurely 42.
In previous works, we found that anti-PrPC antibodies can efficaciously counteract prions 6 – a finding which was later confirmed by several other researchers 43. We speculated that anti-PrPC autoantibodies from the general population could represent a reservoir of potential therapeutic agents against prion diseases. We find, however, that the distribution of titers appears similar between mutation carriers and controls, and between symptomatic and pre-symptomatic mutation carriers, arguing against the possibility that these autoantibodies are broadly beneficial. This is at variance with a previous, pre-clinical report claiming neuroprotective effects for naturally occurring antibodies to a PrP peptide 9. Similarly, naturally occurring anti-β-amyloid autoantibodies with neuroprotective effects were reported in mice, but did not meet primary cognitive endpoints when tested in a phase III clinical trial 44.
Nonetheless, our work does not rule out the possibility of protective anti-PrP autoantibodies in the general population or in PRNP mutation carriers specifically. Our study was restricted to the assessment of autoantibody levels against full-length, wild-type, recombinant human PrPC. We did not evaluate the presence of antibodies specific to pathogenic PRNP mutations or to neoepitopes created by those mutations. Moreover, it is possible that humans develop antibodies specific to PrPSc, the aggregated form of the prion protein. In our experience such anti-PrPSc antibodies tend to cross-react, at least to some level, with PrPC 45. Another difficulty is that PrPSc structure is very heterogenous in genetic prion diseases: while brains from genetic CJD and sCJD patients show similar patterns of PrPSc, PrPSc is fragmented and of low molecular weight in brains from GSS patients and can show marked variation in individuals with the D178N mutation 2, 46. Future studies will focus on the detection of rare, low-titer anti-PrPSc antibodies which may possess unique prion-clearing properties.
Acknowledgements
The authors wish to acknowledge their deepest gratitude to all individuals who participated in this study. The authors are impressed by the enthusiasm and generosity of the participating patients, which is a constant source of inspiration to perform biomedical research. The authors are grateful to the patients’ families, the CJD Foundation, referring clinicians, and all the members of the National Prion Disease Pathology Surveillance Center for invaluable technical help. The authors wish to thank Anne Kerschenmeyer, Tina Kottarathil and Rita Moos at the University Hospital of Zurich for excellent technical assistance.
The authors would like to thank the EPSRC, BBSRC, ERC and the Frances and Augustus Newman Foundation for financial support. This work was supported by the programs “Investissements d’avenir” ANR-10-IAIHU-06, “Santé Publique France” and supported by grants from NIH (R01NS103848), and CDC (UR8/CCU515004). Karl Frontzek received funding from the Theodor Ida Herzog-Egli Stifung and an unrestricted grant by Ono Pharmaceuticals. Georg Meisl is funded by a Ramon Jenkins Research Fellowship at Sidney Sussex College. Adriano Aguzzi is the recipient of an Advanced Grant of the European Research Council (ERC 250356) and is supported by grants from the Swiss National Foundation (SNF, including a Sinergia grant), the Swiss Initiative in Systems Biology, SystemsX.ch (PrionX, SynucleiX), the Klinische Forschungsschwerpunkte (KFSPs) “small RNAs” and “Human Hemato-Lymphatic Diseases”, and a Distinguished Investigator Award of the Nomis Foundation. Collection of samples at Massachusetts General Hospital was funded by Prion Alliance. The funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Appendix
Appendix 1 – author’s contributions
Appendix 2 – Co-investigators
Footnotes
Author disclosures
Dr. Frontzek received an unrestricted grant by Ono Pharmaceuticals and was funded by the Theodor Ida Herzog-Egli Stiftung.
Dr. Carta reports no disclosures.
Dr. Losa reports no disclosures.
Ms. Epskamp reports no disclosures.
Dr. Meisl is funded by a Ramon Jenkins Research Fellowship at Sidney Sussex College.
Ms. Anane reports no disclosures.
Dr. Brandel reports no disclosures.
Dr. Camenisch reports no disclosures.
Dr. Castillas reports no disclosures.
Dr. Roiter reports no disclosures.
Dr. Haïk reports no disclosures.
Dr. Minikel has received research support in the form of charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals and has consulted for Deerfield Management.
Dr. Knowles received financial support by the EPSRC, BBSRC, ERC and the Frances and Augustus Newman Foundation.
Dr. Lindner was funded by the National Organization for Rare Diseases.
Dr. Lutterotti reports no disclosures.
Dr. Safar reports no disclosures.
Dr. Sanchez-Valle reports no disclosures.
Dr. Žáková reports no disclosures.
Dr. Hornemann is the recipient of grants from SystemsX.ch (SynucleiX) and the innovations commission of the University Hospital of Zurich.
Dr. Aguzzi is the recipient of an Advanced Grant of the European Research Council (ERC 250356) and is supported by grants from the Swiss National Foundation (SNF, including a Sinergia grant), the Swiss Initiative in Systems Biology, SystemsX.ch (PrionX, SynucleiX), the Klinische Forschungsschwerpunkte (KFSPs) “small RNAs” and “Human Hemato-Lymphatic Diseases”, and a Distinguished Investigator Award of the Nomis Foundation.
References
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos